BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19738029)

  • 1. BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta.
    Pellicano F; Copland M; Jorgensen HG; Mountford J; Leber B; Holyoake TL
    Blood; 2009 Nov; 114(19):4186-96. PubMed ID: 19738029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells.
    Pellicano F; Simara P; Sinclair A; Helgason GV; Copland M; Grant S; Holyoake TL
    Leukemia; 2011 Jul; 25(7):1159-67. PubMed ID: 21483442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
    Copland M; Pellicano F; Richmond L; Allan EK; Hamilton A; Lee FY; Weinmann R; Holyoake TL
    Blood; 2008 Mar; 111(5):2843-53. PubMed ID: 18156496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of nitric oxide in farnesyltransferase inhibitor-mediated apoptosis in chronic myeloid leukemia cells.
    Selleri C; Maciejewski JP; Montuori N; Ricci P; Visconte V; Serio B; Luciano L; Rotoli B
    Blood; 2003 Aug; 102(4):1490-8. PubMed ID: 12714496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination.
    Gómez-Benito M; Marzo I; Anel A; Naval J
    Mol Pharmacol; 2005 Jun; 67(6):1991-8. PubMed ID: 15738311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells.
    Marzo I; Pérez-Galán P; Giraldo P; López-Royuela N; Gómez-Benito M; Larrad L; Lasierra P; Rubio-Félix D; Anel A; Naval J
    Leukemia; 2004 Oct; 18(10):1599-604. PubMed ID: 15356656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
    Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
    Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative proteomics analysis of BMS-214662 effects on CD34 positive cells from chronic myeloid leukaemia patients.
    Balabanov S; Evans CA; Abraham SA; Pellicano F; Copland M; Walker MJ; Whetton AD; Holyoake TL
    Proteomics; 2013 Jan; 13(1):153-68. PubMed ID: 23184491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.
    Carlo-Stella C; Regazzi E; Sammarelli G; Colla S; Garau D; Gazit A; Savoldo B; Cilloni D; Tabilio A; Levitzki A; Rizzoli V
    Blood; 1999 Jun; 93(11):3973-82. PubMed ID: 10339507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
    Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
    Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
    Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
    Chu S; Holtz M; Gupta M; Bhatia R
    Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
    Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY
    Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.
    Järås M; Johnels P; Hansen N; Agerstam H; Tsapogas P; Rissler M; Lassen C; Olofsson T; Bjerrum OW; Richter J; Fioretos T
    Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16280-5. PubMed ID: 20805474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
    Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
    Carter BZ; Mak PY; Mu H; Zhou H; Mak DH; Schober W; Leverson JD; Zhang B; Bhatia R; Huang X; Cortes J; Kantarjian H; Konopleva M; Andreeff M
    Sci Transl Med; 2016 Sep; 8(355):355ra117. PubMed ID: 27605552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small GTPase RAB45-mediated p38 activation in apoptosis of chronic myeloid leukemia progenitor cells.
    Nakamura S; Takemura T; Tan L; Nagata Y; Yokota D; Hirano I; Shigeno K; Shibata K; Fujie M; Fujisawa S; Ohnishi K
    Carcinogenesis; 2011 Dec; 32(12):1758-72. PubMed ID: 21890458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.
    Liu Z; Li Y; Lv C; Wang L; Song H
    Biochem Biophys Res Commun; 2016 Sep; 478(2):893-9. PubMed ID: 27520370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.